Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 13/20 | 0.72 |
| ▸ | MMP9 | P14780 | 11/20 | 0.72 |
| ▸ | MMP3 | P08254 | 8/20 | 0.72 |
| ▸ | MMP13 | P45452 | 8/20 | 0.72 |
| ▸ | MMP1 | P03956 | 7/20 | 0.72 |
| ▸ | MMP7 | P09237 | 7/20 | 0.72 |
| ▸ | ADAMTS4 | O75173 | 6/20 | 0.72 |
| ▸ | MMP14 | P50281 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6800772 | 0.90 | MMP2 (0.77) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL6799131 | 0.89 | MMP9 (0.60) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL3973093 | 0.86 | MMP2 (0.82) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL21451101 | 0.86 | MMP2 (0.82) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL6561375 | 0.86 | MMP2 (0.82) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL6798909 | 0.85 | ADAMTS4 (0.70) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL6800775 | 0.84 | MMP9 (0.52) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL1750956 | 0.84 | MMP2 (1.00) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL4653257 | 0.84 | MMP2 (1.00) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL32691806 | 0.84 | MMP2 (1.00) | MMP2MMP9MMP3MMP13MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0977745-B1 | THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS | PHARMACIA CORP (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040034071-A1 | Thioaryl sulfonamide hydroxamic acid compounds | PHARMACIA CORPORATION | 2004-02-19 | — | — | US | disclosed |
| EP-0977745-A1 | THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998039313-A1 | THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034071-A1 | Thioaryl sulfonamide hydroxamic acid compounds | MMP10, MMP1, MMP3 | MMP2 4/4885MMP9 8/4885MMP3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.